This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/resource/domain/vavai/subjekt/
n5http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61389013%3A_____%2F14%3A00424592%21RIV14-AV0-61389013/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61389013%3A_____%2F14%3A00424592%21RIV14-AV0-61389013
rdf:type
skos:Concept n5:Vysledek
dcterms:description
As an emerging research direction, nanomedicine has been increasingly utilized to treat inflammatory diseases. In this head-to-head comparison study, four established nanomedicine formulations of dexamethasone, including liposomes (L-Dex), core-cross-linked micelles (M-Dex), slow releasing polymeric prodrugs (P-Dexslow), and fast releasing polymeric prodrugs (P-Dex-fast), were evaluated in an adjuvant-induced arthritis rat model with an equivalent dose treatment design. It was found that after a single i.v. injection, the formulations with the slower drug release kinetics (i.e., M-Dex and P-Dex-slow) maintained longer duration of therapeutic activity than those with relatively faster drug release kinetics, resulting in better joint protection. This finding will be instructional in the future development and optimization of nanomedicines for the clinical management of rheumatoid arthritis. The outcome of this study also illustrates the value of such head-to-head comparison studies in translational nanomedicine research. As an emerging research direction, nanomedicine has been increasingly utilized to treat inflammatory diseases. In this head-to-head comparison study, four established nanomedicine formulations of dexamethasone, including liposomes (L-Dex), core-cross-linked micelles (M-Dex), slow releasing polymeric prodrugs (P-Dexslow), and fast releasing polymeric prodrugs (P-Dex-fast), were evaluated in an adjuvant-induced arthritis rat model with an equivalent dose treatment design. It was found that after a single i.v. injection, the formulations with the slower drug release kinetics (i.e., M-Dex and P-Dex-slow) maintained longer duration of therapeutic activity than those with relatively faster drug release kinetics, resulting in better joint protection. This finding will be instructional in the future development and optimization of nanomedicines for the clinical management of rheumatoid arthritis. The outcome of this study also illustrates the value of such head-to-head comparison studies in translational nanomedicine research.
dcterms:title
Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes
skos:prefLabel
Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes
skos:notation
RIV/61389013:_____/14:00424592!RIV14-AV0-61389013
n5:predkladatel
n6:ico%3A61389013
n3:aktivita
n11:I
n3:aktivity
I
n3:cisloPeriodika
1
n3:dodaniDat
n4:2014
n3:domaciTvurceVysledku
n14:8890390 n14:2802007 n14:4763173
n3:druhVysledku
n10:J
n3:duvernostUdaju
n7:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
31520
n3:idVysledku
RIV/61389013:_____/14:00424592
n3:jazykVysledku
n16:eng
n3:klicovaSlova
nanomedicine; drug targeting; inflammation
n3:klicoveSlovo
n12:inflammation n12:nanomedicine n12:drug%20targeting
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[D8F7FBB5EFA9]
n3:nazevZdroje
ACS Nano
n3:obor
n17:CD
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
16
n3:rokUplatneniVysledku
n4:2014
n3:svazekPeriodika
8
n3:tvurceVysledku
Lammers, T. Mikuls, T. R. Rijcken, C. J. F. Kiessling, F. Etrych, Tomáš Quan, L. Crielaard, B. J. Hennink, W. E. Storm, G. Kostková, Hana Metselaar, J. M. Wang, D. Ulbrich, Karel Lele, S. M. Dusad, A. Zhang, Y.
n3:wos
000330542900045
s:issn
1936-0851
s:numberOfPages
9
n18:doi
10.1021/nn4048205